Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris

ClinicalTrials.gov ID: NCT00306878

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00306878. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this clinical research study is to determine the safety, pharmacokinetics, immunogenicity in humans, the recovery time required from the biologic effects and the optimal biologic dose range of BMS188667 (CTLA4Ig)

Study identification

NCT ID: NCT00306878
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: 45 participants

Conditions and interventions

Conditions

Psoriasis Vulgaris

Interventions

Abatacept Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 50 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 1995 (Type not available)
Primary completion: May 1997 (Actual)
Completion: May 1997 (Actual)
Last update posted: Apr 13, 2011

1995 – 1997

United States locations

U.S. sites: 5
U.S. states: 4
U.S. cities: 5

Facility	City	State	ZIP	Site status
Local Institution	Boston	Massachusetts	—	—
Local Institution	Ann Arbor	Michigan	—	—
Local Institution	New York	New York	—	—
Local Institution	Philadelphia	Pennsylvania	—	—
Local Institution	Pittsburgh	Pennsylvania	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00306878, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 13, 2011 · Synced Nov 12, 2026